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Background: Gastric cancer (GC) is the third leading cause of cancer death in China and the outcome of GC
patients is poor. The aim of the research is to study the prognostic factors of gastric cancer patients who had
curative intent or palliative resection, completed clinical database and follow-up.
Methods: This retrospective study analyzed 533 GC patients from three tertiary referral teaching hospitals from January
2004 to December 2010 who had curative intent or palliative resection, complete clinical database and follow-up
information. The GC-specific overall survival (OS) status was determined by the Kaplan-Meier method, and univariate
analysis was conducted to identify possible factors for survival. Multivariate analysis using the Cox proportional hazard
model and a forward regression procedure was conducted to define independent prognostic factors.
Results: By the last follow-up, the median follow-up time of 533 GC patients was 38.6 mo (range 6.9-100.9 mo), and
the median GC-specific OS was 25.3 mo (95% CI: 23.1-27.4 mo). The estimated 1-, 2-, 3- and 5-year GC-specific OS rates
were 78.4%, 61.4%, 53.3% and 48.4%, respectively. Univariate analysis identified the following prognostic factors: hospital,
age, gender, cancer site, surgery type, resection type, other organ resection, HIPEC, LN status, tumor invasion, distant
metastases, TNM stage, postoperative SAE, systemic chemotherapy and IP chemotherapy. In multivariate analysis, seven
factors were identified as independent prognostic factors for long term survival, including resection type, HIPEC, LN status,
tumor invasion, distant metastases, postoperative SAE and systemic chemotherapy.
Conclusions: Resection type, HIPEC, postoperative SAE and systemic chemotherapy are four independent prognostic
factors that could be intervened for GC patients for improving survival.
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Gastric cancer (GC) remains the second leading cause of
cancer death worldwide [1], accounting for 8% of the
total cases and 10% of total deaths in 2008 [2]. In China,
GC is the third leading cause of cancer death [3] and the
outcome of GC patients is poor, especially for patients at
advanced stage, and the 5-year survival rate is less than
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reproduction in any medium, provided the orEarly diagnosis and early treatment remain the best strat-
egy for GC. In China, however, a majority of GC patients
are not early cancer by the time when they seek medical at-
tention [5,6]. Therefore, surgery-based multidisciplinary
treatment approach is warranted in order to improve both
overall survival (OS) and the quality of life.
Despite this common-sense knowledge, there is no
commonly accepted multidisciplinary treatment strat-
egy in China, primarily due to the lack of large data-
base information reflecting the clinical reality of the
current treatment situation.
In our previous studies on GC patients, we evaluated
the common tumor markers for the diagnosis of gastric
cancer. In these relatively large cohort studies, stage III
and beyond patients accounted for over 65% of the en-
tire patient population [6,7], a result similar to othertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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longer a local disease, but at least a regional or a sys-
temic disease.
Currently, surgery remains the most effective therapy
for GC, offering an excellent chance (90%) of a cure for
early GC patients [9]. Surgical procedures have a big im-
pact on OS and recurrence [10]. R0 resection with D2
lymphadenectomy is regarded as the standard surgical
technique [11,12], as D2 lymphadenectomy had lower
recurrence and GC-related death rates [13]. However,
for stage III and beyond patients, the currently adopted
surgical procedure only removes local tumor mass but
often neglects the micro-metastases. Therefore, add-
itional adjuvant therapies are required to ensure better
treatment efficacy.
Over the past years, our database has grown bigger and
more detailed information on major clinico-pathological
characteristics has been accumulated. Therefore, we con-
ducted this comprehensive analysis of the data collected
from three major teaching hospitals in Central China, so
as to gain deeper insights to the major features of GC in
central China and to identify independent factors for
prognosis that could be intervened.
Methods
Ethics statement
All patients provided written informed consent for their
information to be stored in the hospital database; and
we obtained separate consent for research. Study ap-
proval was obtained from independent ethics commit-
tees from Zhongnan Hospital of Wuhan University. The
study was undertaken in accordance with the ethical
standards of the World Medical Association Declaration
of Helsinki.
Patients
This study included a total of 533 GC patients from
three tertiary referral hospitals, from January 2004 to
December 2010. These patients underwent resection
with curative intent (D2 lymphadenectomy) or palliative
resection. All the detailed clinic-pathological information
was available, including demographic variables, underlying
co-morbidities, surgical modality, lab and image study in-
formation, pathological reports, pre- and post-operative
therapies, and follow-up information. Pathological informa-
tion was mainly focused on tumor type, pathological grad-
ing, TNM stages, blood vessel or neural invasions. The
pathologic staging was based on the 7th edition of AJCC
staging criteria [14]. Postoperative treatments were focused
on chemotherapy regimens and cycles, and radiotherapy if
applicable. GC patients with T2 or higher, any N tumors
should receive systemic chemotherapy except patients
who declined the offer [15]. Hyperthermic intraperitoneal
chemotherapy (HIPEC) and intraperitoneal chemotherapy(IP chemotherapy) were adjuvant chemotherapy, and only
those who had peritoneal carcinomatosis (PC) should re-
ceive [16]. In our study, the systemic chemotherapy admin-
istered were mainly FOLFOX4 and FOLFOX6, HIPEC
were mainly using lobaplatin and paclitaxel, and IP chemo-
therapy were docetaxel and carboplatin.
These patients were followed-up every 3 months dur-
ing the first 2 years after operation, every 6 months on
the third postoperative year and every year thereafter.
All the follow-up information was incorporated into a
standardized database.Database construction
The above-mentioned information was incorporated into
a central database, set up at the Zhongnan Hospital of
Wuhan University, which undergoes regular updating
every 3 months.Statistical analysis
All eligibility cases from the central database were analyzed
by SPSS 17.0 statistical package software (SPSS Inc.,
Chicago, IL, USA). The variables were hospital (Zhongnan
Hospital, Heji Hospital or Hubei Tumor Hospital), gender
(male or female), age (≤65 yr or > 65 yr), cancer site (upper
third [excluding squamous cell carcinoma at gastroesopha-
geal junction], middle third, lower third or whole stomach),
pathological type (well or intermediately differentiated
adenocarcinoma, poorly differentiated or undifferentiated
carcinoma, signet ring cell carcinoma or mucious adenocar-
cinoma or others), surgery type (proximal gastrectomy, dis-
tal gastrectomy or total gastrectomy), resection type (for
stomach itself) (palliative resection or curative resection),
other organ resection (mainly included liver, spleen, intes-
tines, ovarian, ovarian ducts) (0, 1, 2 or ≥ 3), HIPEC (yes or
no), lymph node status (LN status) (N0, N1, N2 or N3),
tumor invasion (T1, T2, T3, T4a or T4b), distant metastasis
(M0 or M1), pathological stage (I, II, IIIA, IIIB, IIIC or IV)
[14], postoperative serious adverse event (postoperative
SAE) (defined as life threatening events after operation, in-
cluding gastrointestinal obstruction, anastomotic leakage,
and bleeding leading to grade 3 and above anemia, abdom-
inal abscess) (yes or no), systemic chemotherapy (0, 1 to 6
cycles or > 6 cycles), IP chemotherapy (yes or no), GC-
specific overall survival (GC-specific OS, defined as the
time interval from first treatment to GC-specific death,
with the last follow-up time on May 31, 2012).
The numerical data was analyzed directly. The category
data was converted when necessary. The Kaplan-Meier sur-
vival curve was used to study the survival status, using log
rank test to decipher the statistical significance, which was
judged as P < 0.05 throughout this study.
To work out independent factors for survival, a Cox
proportional hazard model was used to first obtain the
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cedure to finally identify the independent factors.
Results
Characteristics of the patients
A total of 533 patients with GC were recruited from 3
tertiary referral teaching hospitals, including 194 patients
from Zhongnan Hospital of Wuhan University, 182 pa-
tients from Heji Hospital and 157 patients from Hubei
Tumor Hospital. By the time of last follow-up, 278
deaths (52.2%) occurred, including 126 deaths (64.9%)
out of 194 enrolled patients from Zhongnan Hospital of
Wuhan University, 84 deaths (46.2%) out of 182 enrolled
patients from Heji Hospital, and 68 deaths (43.3%) out
of 157 enrolled patients from Hubei Tumor Hospital. The
median age of cases was 58 years (range 20–85 years), and
male-to-female ratio was 2.7 to 1. Detailed information on
major demographic and clinico-pathological characteristics
was listed in Table 1.
GC-specific OS
By the time of last follow-up, the median follow-up time
was 38.6 mo (range 6.9-100.9 mo), and 278 patients died
out of the entire 533 assessable patients (52.2%). The
median GC-specific OS was 25.3 mo (95% CI: 23.1-27.4
mo). The survival curve by stages was shown in Figure 1.
The estimated 1-, 2-, 3- and 5-year GC-specific OS rates
were 78.4%, 61.4%, 53.3% and 48.4%, respectively. The
median survival by stages I, II, IIIA, IIIB, IIIC and IV
were 85.2 mo (95% CI: 76.1-94.3 mo), 53.9 mo (95% CI:
46.6-61.3 mo), 40.0 mo (95% CI: 21.7-58.3 mo), 28.0 mo
(95% CI: 14.9-41.1 mo), 14.8 mo (95% CI: 10.6-19.1 mo)
and 11.1 mo (95% CI: 9.7-12.4 mo), respectively. As
shown in Figure 1, significant differences in GC-specific
OS were found among different clinical stages. Patients
at clinical stage IIIB and beyond had much poorer GC-
specific OS status than other patients.
Mortality analysis
By the time of last follow-up, 278 patients (52.2%) died
among the entire 533 assessable patients. In terms of ab-
solute number of patient death on the yearly basis, there
were 114 (41.0%), 92 (33.1%), 43 (15.5%), 18 (6.5%), 8
(2.9%) deaths, respectively, in the 1st, 2ed, 3rd, 4th, and
5th postoperative year. Only 3 (1.1%) deaths occurred
after 5 years. Information on GC-specific death in rela-
tionship with clinical stages was depicted in Figure 2.
Putting together, there were 249 (89.6%) deaths within
three years after operation.
Univariate survival analysis
In this study, all variables were analyzed by Kaplan-
Meier curve and log-rank test. Among these variables,
pathological type had no statistically significant impacton GC-specific OS (P = 0.212), but statistically significant
factors were hospital (P = 0.008), age (P < 0.001), gender
(P = 0.019), cancer site (P = 0.004), surgery type (P < 0.001),
resection type (P < 0.001), other organ resection (P < 0.001),
HIPEC (P < 0.001), LN status (P < 0.001), tumor invasion
(P < 0.001), distant metastases (P < 0.001), TNM stage (P <
0.001), postoperative SAE (P < 0.001), systemic chemother-
apy (P = 0.001), and IP chemotherapy (P = 0.003) (Table 1).
Multivariate survival analysis
After univariate survival analysis, the above significant
factors were further subjected to multivariate analysis
using Cox proportional hazard model and forward re-
gression procedure. The following variables were iden-
tified as independent factors for prognosis: tumor
invasion (P < 0.001), LN status (P < 0.001), distant me-
tastases (P < 0.001), resection type (P = 0.015), HIPEC
(P = 0.049), postoperative SAE (P < 0.001) and systemic
chemotherapy (P < 0.001) (Table 2).
Discussion
Several important points should be considered from this
study. First, a majority of GC patients are at advanced
clinical stage. In our series of 533 patients, 354 cases
(66.4%) were clinically stage III and beyond. For these
patients, GC is no longer a local disease, but at least a
regional or a systemic disease. Although surgery could
remove the bulky tumor mass itself, it may leave some un-
seen cancer cells in the operating field. Therefore, more
intensive adjuvant chemotherapy should be followed in
order to eradicate these left-over cancer cells. Two large
scale randomized clinical trials have already demonstrated
the superiority of this approach over conventional surgery
alone [17,18]. Another reasonable approach is to start peri-
operative chemotherapy, to down-stage the tumor, followed
by curative resection. It has been proven that such a treat
modality indeed could improve the clinical outcomes of
GC patients [19].
Secondly, our analysis found that over 40% of GC death
occurred in the first year after operation, and another 30%
plus of GC death occurred during the second year after op-
eration [20-22]. Therefore, it is clinically important to de-
sign rational strategies to address these problems. One key
consideration is that high risk factors should be investigated
and identified, so as to reduce them and reduce the death
risk. Another strategy is to design a close follow-up plan
and strictly implement it, so as to identify those patients
with early signs of recurrence and apply appropriate therap-
ies. Among the currently used methods, serum tumor
markers study and medical imaging studies are most widely
used approaches. Regular monitoring blood tumor markers
carcinoembryonic antigen (CEA) and carboxyl antigen 19–
9 (CA19-9) could help provide warning information on
cancer recurrence [23].
Table 1 Characteristics of the 533 GC patients enrolled into this study
Variables Total n (%) Events n (%) Median GC-specificOS (95% CI) (mo) P value
Age (yr)
≤ 65 380 (71.3) 178 (46.8) 51.7 (39.7-63.7)
< 0.001
> 65 153 (28.7) 100 (65.4) 28.0 (21.6-34.4)
Gender
Male 389 (73.0) 192 (49.4) 39.7 (29.9-49.5)
0.019
Female 144 (27.0) 86 (59.7) 28.0 (17.9-38.1)
Cancer site
Upper third 156 (29.3) 80 (51.3) 32.6 (25.9-39.3)
0.004
Middle third 119 (22.3) 61 (51.3) 38.9 (9.4-68.4)
Lower third 222 (41.7) 112 (50.5) 42.1 (34.2-49.9)
Whole stomach 36 (6.8) 25 (69.4) 13.2 (10.1-16.3)
Pathological type
Adeno WD/ID 131 (24.6) 59 (45.0) 42.1 (29.9-54.2)
0.212
Adeno PD/UN 299 (56.1) 160 (53.5) 34.9 (27.5-42.4)
Signet ring/mucious Ca 85 (15.9) 49 (57.6) 28.0 (10.9-45.1)
Others 18 (3.4) 10 (55.6) 33.7 (20.0-47.5)
Surgery type
Proximal gastrectomy 169 (31.7) 82 (48.5) 35.9 (20.5-51.3)
< 0.001Distal gastrectomy 268 (50.3) 128 (47.8) 46.6 (38.1-55.1)
Total gastrectomy 96 (18.0) 68 (70.8) 17.4 (11.3-23.4)
Resection type
Palliative resection 11 (2.1) 11 (100.0) 9.8 (8.0-11.6)
< 0.001
Curative resection 522 (97.9) 267 (51.1) 38.9 (31.8-46.0)
Other organ resection (n)
0 507 (95.1) 256(50.5) 39.3 (32.5-46.0)
< 0.001
1 14 (2.6) 11 (78.6) 24.1 (9.6-38.7)
2 8 (1.5) 7 (87.5) 12.4 (2.7-22.2)
≥ 3 4 (0.8) 4 (100.0) 13.6 (2.7-24.4)
HIPEC
No 505 (94.7) 251 (49.7) 39.7 (32.4-47.0)
< 0.001
Yes 28 (5.3) 27 (96.4) 13.4 (9.6-17.2)
LN status
N0 172 (32.3) 51 (29.7) 67.3 (59.8-74.8)
< 0.001
N1 112 (21.0) 57 (50.9) 35.9 (26.8-45.0)
N2 143 (26.8) 86 (60.1) 27.0 (19.9-34.1)
N3 106 (20.0) 84 (30.5) 14.4 (12.0-16.8)
Tumor invasion
T1 25 (4.7) 3 (12.0) 75.4 (66.4-84.4)
< 0.001
T2 85 (15.9) 19 (22.4) 72.7 (62.2-83.2)
T3 2 (0.4) 1 (50.0) 29.1 (10.7-47.4)
T4a 332 (62.3) 187 (56.3) 33.0 (26.6-39.4)
T4b 89 (16.7) 68 (76.4) 14.8 (10.8-18.9)
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Table 1 Characteristics of the 533 GC patients enrolled into this study (Continued)
Distant metastases
No 478 (89.7) 224 (46.9) 42.5 (34.6-50.4)
< 0.001
Yes 55 (10.3) 54 (98.2) 10.6 (9.0-12.1)
TNM staging
Stage I 79 (14.8) 8 (10.1) 85.2 (76.1-94.3)
< 0.001
Stage II 100 (18.8) 35 (35.0) 53.9 (46.6-61.3)
Stage IIIA 80 (15.0) 38 (47.5) 40.0 (21.7-58.3)
Stage IIIB 116 (21.8) 67 (57.8) 28.0 (14.9-41.1)
Stage IIIC 117 (22.0) 90 (76.9) 14.8 (10.6-19.1)
Stage IV 41 (7.7) 40 (97.6) 11.1 (9.7-12.4)
Postoperative SAE
No 458 (85.9) 205 (44.8) 49.8 (32.5-67.0)
< 0.001
Yes 75 (14.1) 73 (97.3) 14.8 (10.0-19.6)
Systemic chemotherapy (cycles)
0 217 (40.7) 128 (59.0) 26.3 (19.2-33.4)
0.0011 to 6 302 (56.7) 142 (47.0) 51.7 (36.6-66.9)
> 6 14 (2.6) 8 (57.1) 37.8 (16.9-58.7)
IP chemotherapy
No 521 (97.7) 267 (51.2) 37.0 (29.8-44.2)
0.003
Yes 12 (2.3) 11 (91.7) 11.1 (7.0-15.1)
GC: gastric cancer; GC-specific OS: gastric cancer-specific overall survival; Adeno WD/ID: well differentiated or intermediately differentiated adenocarcinoma;
Adeno PD/UN: poorly differentiated or undifferentiated carinoma; Signet ring/mucious Ca: Signet ring cell carcinoma or mucious adenocarcinoma; HIPEC:
hyperthermic intraperitoneal chemotherapy; LN status: lymph node status; SAE: serious adverse event; IP chemotherapy: intraperitoneal chemotherapy.
Figure 1 Kaplan-Meier survival curve of the 533 GC patients in this study.
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Figure 2 Information on GC-specific deaths in relationship with
clinical stages.
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impact on GC-specific OS, such as age, gender, cancer site,
surgery type, resection type, other organ resection, HIPEC,
LN status, tumor invasion, distant metastases, TNM stage,
postoperative SAE, systemic chemotherapy and IP chemo-
therapy [5,7,8,20,24-28]. These results are in accordance
with our study. In our study, pathological type had no im-
pact on GC-specific OS, which is not in conformity with
several previous studies that concluded that pathological
type was an important factor for prognosis and survival of
GC [5,24], but is in agreement with some other studies that
reported that pathological type had no influence on GC-
specific OS [7,27]. This could be due to the different typing
method used. It has been documented that Lauren histo-
logical classification is a simple and practical typing method
to have significant correlation with survival of GC. Clinical-
pathological information of this study was obtained from
hospital department of pathology, and they did not adopt
Lauren classification. In future studies, we should adopt this
classification.Table 2 Independent prognostic factors of 533 GC
patients identified by multivariate analysis
Covariate χ2 P HR 95% CI
Lower Upper
Tumor invasion 13.008 < 0.001 1.022 1.010 1.034
LN status 36.845 < 0.001 1.462 1.293 1.653
Distant metastases 29.004 < 0.001 2.832 1.939 4.137
Resection type 5.900 0.015 0.430 0.218 0.850
HIPEC 3.863 0.049 1.707 1.001 2.910
Postoperative SAE 27.752 < 0.001 2.507 1.781 3.528
Systemic chemotherapy 24.064 < 0.001 0.521 0.402 0.676
GC: gastric cancer; HR: hazard ratio; CI: confidence interval; LN status: lymph
node status; HIPEC: hyperthermic intraperitoneal chemotherapy; SAE: serious
adverse event.For cancer patients, the clinical outcomes depend on
several important factors, which could be divided into
those that cannot be intervened such as TNM stage, and
those can be intervened such as treatment models. After
the Cox proportional hazard model analysis, we worked
out seven independent factors that had significant im-
pact on survival, six of these seven factors have already
been well recognized as the most important determi-
nants of patients’ survival [5,7,8,29]. What deserves
special attention is the finding that HIPEC is also an in-
dependent factor for improved survival. Several phases I
to III studies have already demonstrated the treatment
advantage of HIPEC. Glehen et al. consecutively treated
49 advanced GC patients with HIPEC, which resulted in
10.3 months of GC-specific OS, against 6.1 months of
GC-specific OS treated with only standard curative resec-
tion [30]. In another study by Yonemura et al., 107 GC pa-
tients also treated with HIPEC, and the GC-specific OS
was 11.5 months [31]. More importantly, a recent phase III
prospective randomized clinical trial also confirmed the
survival advantage of 11.0 months in the HIPEC group
against 6.5 months in the CRS group [32]. In addition, a
systematic review and meta-analysis of 13 acceptable qual-
ities randomized controlled trials also have established that
HIPEC has significant survival advantage over the currently
standard treatment for advanced GC [33]. Taken together,
all these facts confirm the value of HIPEC for the treatment
of stage III and beyond GC patients. In this study, the me-
dian survival of patients with HIPEC was 13.4 mo (95% CI:
9.6-17.2), which was shorter than others without HIPEC
(39.7 mo [95% CI: 32.4-47.0]). It was due to patients with
HIPEC were gastric cancer with metastasis and prognosis
was not optimistic. However, the median survival of pa-
tients with HIPEC was longer than patients with metastasis
(13.4 mo vs 10.6 mo, P < 0.05). It supports HIPEC has sig-
nificant survival advantage even though there could be se-
lection bias in this regard, due to the limited number of
patients treated by HIPEC.
Postoperative SAE included gastrointestinal obstruc-
tion, anastomotic leakage, and bleeding leading to grade
3 and above anemia, abdominal abscess. All these have
been confirmed to have a significant negative impact on
GC-specific OS. In the study of Sierzega et al. [34], the
median OS of patients with anastomotic leakage was sig-
nificantly lower than patients with non-anastomotic leakage
(4.1 mo vs. 23 mo, P < 0.001), and the progression-free sur-
vival of patients with anastomotic leakage was also signifi-
cantly shorter than patients with non-anastomotic leakage
(11 mo vs. 19 mo, P = 0.021). In another study by Yoo et al.
[35], the mean OS of patients with anastomotic leakage was
significantly lower than patients with non-anastomotic leak-
age (30.5 mo vs. 96.2 mo, P < 0.001). Anastomotic leakage
could promote gastric cancer progression by prolonging in-
flammation [34-36]. According to Tokunaga et al. [37], GC
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OS rate and 5-relapse-free survival rate than patients with-
out intra-abdominal infectins (66.4% vs. 86.8%, P < 0.001
and 64.9% vs. 84.5%, P < 0.001). In another study by Li et al.
[38], postoperative complications including gastrointestinal
obstruction, anastomotic leakage, and bleeding leading and
abdominal abscess all were independent and negative prog-
nostic factors for GC. Therefore, all efforts should be made
to reduce the risk for postoperative SAE, including careful
patient selection for surgery and optimized perioperative
patient care.
Conclusion
In summary, this study identified four independent prog-
nostic factors that could be intervened for GC patients,
including curative resection, HIPEC, postoperative SAE
and systemic chemotherapy, and three independent prog-
nostic factors that cannot be intervened: tumor invasion,
LN status and distant metastasis. Therefore, increasing
attention should be directed at better understanding tumor
biology involved in cancer invasion and metastasis, and
refining multi-disciplinary comprehensive treatment strat-
egies to enhance efficacy and reduce SAE.
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